N-(8-tert-butyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-acetamide | 1066567-51-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-(8-tert-butyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-acetamide
• 英文别名: N-(8-tert-butyl-4,5-dihydro-[1,3]thiazolo[4,5-h]quinazolin-2-yl)acetamide
• CAS: 1066567-51-8
• 化学式: C₁₅H₁₈N₄OS
• 分子量: 302.4
• InChiKey: UNHAPQCHMNILOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  96
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(8-tert-butyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-acetamide 在 盐酸 、 水 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 (R)-2-dimethylaminomethyl-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-[(8-tert-butyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)amide]
  参考文献：
  名称：

  Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors

  摘要：

  A cyclisation within a 4',5-bisthiazole (S)-proline-amide-urea series of selective PI3K alpha inhibitors led to a novel 4,5-dihydrobenzo[1,2-d: 3,4-d] bisthiazole tricyclic sub-series. The synthesis and optimisation of this 4,5-dihydrobenzo[1,2-d: 3,4-d] bisthiazole sub-series and the expansion to a related tricyclic 4,5-dihydrothiazolo[4,5-h] quinazoline sub-series are described. From this work analogues including 11, 12, 19 and 23 were identified as potent and selective PI3K alpha inhibitor in vivo tool compounds. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.06.067
• 作为产物：
  描述：

  N-(6-formyl-7-oxo-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide 、 2,2-二甲基丙亚胺盐酸 在 吡啶 作用下， 反应 6.5h， 生成 N-(8-tert-butyl-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl)-acetamide
  参考文献：
  名称：

  2-Carboxamide Cycloamino Ureas

  摘要：

  本发明涉及公式I的化合物及其盐，其中取代基如描述中所定义，以及该化合物在治疗通过抑制磷脂酰肌醇3-激酶改善的疾病中的应用。

  公开号：

  US20110003786A1

文献信息

• 2-CARBOXAMIDE CYCLOAMINO UREAS USEFUL AS PI3K INHIBITORS
  申请人：Novartis AG

  公开号：EP2448946A1

  公开（公告）日：2012-05-09
• US8357707B2
  申请人：——

  公开号：US8357707B2

  公开（公告）日：2013-01-22
• [EN] 2-CARBOXAMIDE CYCLOAMINO UREAS USEFUL AS PI3K INHIBITORS<br/>[FR] 2-CARBOXAMIDE CYCLOAMINO URÉES UTILES EN TANT QU'INHIBITEURS DE LA PI3K
  申请人：NOVARTIS AG

  公开号：WO2011000855A1

  公开（公告）日：2011-01-06

  The present invention relates to compounds of formula (I) and sails thereof, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.
• 2-Carboxamide Cycloamino Ureas
  申请人：FAIRHURST Robin Alec

  公开号：US20110003786A1

  公开（公告）日：2011-01-06

  The present invention relates to compounds of formula I and salts thereof, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.

  本发明涉及公式I的化合物及其盐，其中取代基如描述中所定义，以及该化合物在治疗通过抑制磷脂酰肌醇3-激酶改善的疾病中的应用。
• Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors
  作者：Robin A. Fairhurst、Marc Gerspacher、Patricia Imbach-Weese、Robert Mah、Giorgio Caravatti、Pascal Furet、Christine Fritsch、Christian Schnell、Joachim Blanz、Francesca Blasco、Sandrine Desrayaud、Daniel A. Guthy、Mark Knapp、Dorothee Arz、Jasmin Wirth、Esther Roehn-Carnemolla、Van Huy Luu

  DOI：10.1016/j.bmcl.2015.06.067

  日期：2015.9

  A cyclisation within a 4',5-bisthiazole (S)-proline-amide-urea series of selective PI3K alpha inhibitors led to a novel 4,5-dihydrobenzo[1,2-d: 3,4-d] bisthiazole tricyclic sub-series. The synthesis and optimisation of this 4,5-dihydrobenzo[1,2-d: 3,4-d] bisthiazole sub-series and the expansion to a related tricyclic 4,5-dihydrothiazolo[4,5-h] quinazoline sub-series are described. From this work analogues including 11, 12, 19 and 23 were identified as potent and selective PI3K alpha inhibitor in vivo tool compounds. (C) 2015 Elsevier Ltd. All rights reserved.